![Neil Torres](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Neil Torres
Direktor/Vorstandsmitglied bei
Systems Oncology LLC
Profil
Neil Torres is currently the Director at Systems Oncology LLC and Principal at The Pritzker Organization LLC since 2002.
Mr. Torres completed undergraduate education at The University of Chicago in 2002.
Aktive Positionen von Neil Torres
| Unternehmen | Position | Beginn |
|---|---|---|
Systems Oncology LLC
 Systems Oncology LLC BiotechnologyHealth Technology Researches and develops cancer drugs | Direktor/Vorstandsmitglied | - |
The Pritzker Organization LLC
 The Pritzker Organization LLC Investment ManagersFinance The Pritzker Organization invests in companies located in the United States with an enterprise value of USD 100 - 1000 billion and an EBITDA of USD 10 - 150 million. The firm targets companies operating across a broad range of sectors and industries. It provides financing for growth stage capital requirements with an investment size of USD 75 -300 million for majority deals & USD 15 - 100 million for minority and structured deals. The firm also acquires majority and minority interest. | Private Equity Investor | 01.06.2002 |
Ausbildung von Neil Torres
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
98
Beziehungen ersten Grades
3
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
The University of Chicago
 The University of Chicago Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Pritzker Organization LLC
The Pritzker Organization LLC Investment ManagersFinance The Pritzker Organization invests in companies located in the United States with an enterprise value of USD 100 - 1000 billion and an EBITDA of USD 10 - 150 million. The firm targets companies operating across a broad range of sectors and industries. It provides financing for growth stage capital requirements with an investment size of USD 75 -300 million for majority deals & USD 15 - 100 million for minority and structured deals. The firm also acquires majority and minority interest. | Finance |
Systems Oncology LLC
Systems Oncology LLC BiotechnologyHealth Technology Researches and develops cancer drugs | Health Technology |
